S. Debruxelles
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
S. Debruxelles has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Francois Rouanet
Bordeaux University Hospital, Stroke Unit, Bordeaux, France
3 shared publications - Igor Sibon
Stroke Unit, Department of Neurology, Bordeaux University Hospital, Bordeaux, France
3 shared publications - Pauline Renou
Bordeaux University Hospital, Stroke Unit, Bordeaux, France
3 shared publications - M. Poli
Bordeaux University Hospital, Stroke Unit, Bordeaux, France
2 shared publications - Stéphane Olindo
Centre Hospitalier Universitaire (CHU) de Bordeaux, Neurologie Vasculaire, France (M. Boullet, S.O., I.S.).
2 shared publications - A. Georget
Bordeaux University Hospital, Methodology Department, Bordeaux, France
1 shared publication
Latest Publications
- 25 June 2024
- Published by Elsevier in Revue Neurologique
- Vol. 180 (10) , 1108-1116
Remote neurological evaluation reliably identifies patients eligible to endovascular therapy while non-eligible to intravenous thrombolysis
- 25 June 2024
- Published by Elsevier in Revue Neurologique
- Vol. 180 (10) , 1108-1116
Remote neurological evaluation reliably identifies patients eligible to endovascular therapy while non-eligible to intravenous thrombolysis
- Open Access
- 25 August 2016
- Published by Springer Nature in BMC Geriatrics
- Vol. 16 (1) , 156
The impact of intravenous thrombolysis on outcome of patients with acute ischemic stroke after 90 years old
Age increases the risk of mortality and poor prognosis following stroke. The benefit of intravenous thrombolysis in very old patients remains uncertain. The purpose of the study was to evaluate the efficacy and safety of thrombolysis in very old patients considering their perfusion-imaging profile. We conducted a retrospective study including patients older than 90 y.o. admitted for an acute ischemic stroke. A computed tomography perfusion-imaging (CTP) was performed in patients who received thrombolysis. Primary outcome was the functional status at 3 months, assessed by the modified Rankin scale (mRS). Secondary outcomes were the rate of hemorrhagic transformations, duration of hospitalization and the rate of death in the first 7 days. Patients receiving thrombolysis were compared with an age-matched group of non-thrombolysed patients. 78 patients were included (31 % male, aged 92 ± 1.7 y.o). 37 patients received thrombolysis and among them, 30 had CTP with a mismatch. The three months mRS was not significantly different in the two groups (mRS 0–2: 5 % and 7 % in the thrombolysed and non-thrombolysed group, respectively). Hemorrhagic transformations were more frequent in the thrombolysed group (54 % versus 12 %, p = 0.002) and symptomatic intracranial hemorrhage tended to be associated with mRS at three months and death in the first 7 days. Duration of hospitalization was longer in the thrombolysed group (10 days ± 12 versus 7 days ± 9, p = 0.046). Patients who received thrombolysis did not have a better functional prognosis than non-thrombolysed patients.
- 25 August 2016
- Published by Springer Nature in BMC Geriatrics
- Vol. 16 (1) , 156
Open AccessThe impact of intravenous thrombolysis on outcome of patients with acute ischemic stroke after 90 years old
Age increases the risk of mortality and poor prognosis following stroke. The benefit of intravenous thrombolysis in very old patients remains uncertain. The purpose of the study was to evaluate the efficacy and safety of thrombolysis in very old patients considering their perfusion-imaging profile. We conducted a retrospective study including patients older than 90 y.o. admitted for an acute ischemic stroke. A computed tomography perfusion-imaging (CTP) was performed in patients who received thrombolysis. Primary outcome was the functional status at 3 months, assessed by the modified Rankin scale (mRS). Secondary outcomes were the rate of hemorrhagic transformations, duration of hospitalization and the rate of death in the first 7 days. Patients receiving thrombolysis were compared with an age-matched group of non-thrombolysed patients. 78 patients were included (31 % male, aged 92 ± 1.7 y.o). 37 patients received thrombolysis and among them, 30 had CTP with a mismatch. The three months mRS was not significantly different in the two groups (mRS 0–2: 5 % and 7 % in the thrombolysed and non-thrombolysed group, respectively). Hemorrhagic transformations were more frequent in the thrombolysed group (54 % versus 12 %, p = 0.002) and symptomatic intracranial hemorrhage tended to be associated with mRS at three months and death in the first 7 days. Duration of hospitalization was longer in the thrombolysed group (10 days ± 12 versus 7 days ± 9, p = 0.046). Patients who received thrombolysis did not have a better functional prognosis than non-thrombolysed patients.
- 1 April 2014
- Published by Elsevier in Revue Neurologique
- Vol. 170, A81-A82
Quel apport des tests d’agrégabilité plaquettaire dans l’orientation étiologique des infarctus cérébraux survenant sous anti-agrégant plaquettaire ?
- 1 April 2014
- Published by Elsevier in Revue Neurologique
- Vol. 170, A81-A82
Quel apport des tests d’agrégabilité plaquettaire dans l’orientation étiologique des infarctus cérébraux survenant sous anti-agrégant plaquettaire ?